EconomyEditor's PickPharmally files complaint vs Hontiveros

November 3, 2021

PHARMALLY Pharmaceutical Corp., which has been under a Senate probe for alleged anomalies in pandemic supply contracts, has filed a sedition complaint against a senator, citing bribery and manipulation.

Company representative Jaime B. Vegas, in a press conference Wednesday after filing the complaint against Senator Ana Theresia “Risa” N. Hontiveros-Baraquel, said his co-worker, Veejay Almira, was subjected to manipulation by the solon.

The senator’s chief legislative officer, Ryan T. Lazo, and several others are also named respondents in the case.

Mr. Almira appeared before the Senate Blue Ribbon committee on Sept. 24, where he said that the company delivered expired and substandard face shields meant for medical professionals to the Health department.

Ms. Hontiveros has denied the accusations saying it was Mr. Almira himself who reached out to her office.

“We also have a whole narrative of Veejay pledging in front of notary public that will prove his testimony,” Ms. Hontiveros said in a press conference Wednesday.

“The charge to commit sedition is laughable… I do not need to resort to unlawful means to point out anomalies in Pharmally’s transactions,” she said. “This is clearly a last-ditch effort by Pharmally and its backers.” — Alyssa Nicole O. Tan

Leave a Reply

Your email address will not be published. Required fields are marked *

Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartPeopleMail. All Rights Reserved.

Subscribe for FREE today and get your daily shot of smart news about the Economy and Investing.
We are dedicated to keeping any data we collect from you — safe and secure. Here you can read our privacy policy.